P021

P021 is a synthetic neurotrophic peptide — a small, chemically modified fragment built to boost brain growth-factor signaling — that has improved memory in mouse models of Alzheimer’s disease. P021 is not FDA-approved and has never been tested in a human trial. The rodent science is promising; the human proof does not exist yet.

What is P021?

P021 is a lab-made peptidomimetic — a short peptide-like molecule engineered from a four-amino-acid core (aspartate–glycine–glycine–leucine, or “DGGL”). Chemists acetylated one end and capped the other with an adamantane group (a rigid, cage-shaped carbon structure) so the molecule survives digestion and can cross into the brain, which most peptides can’t. Its formula is C27H42N6O8, its molecular weight is about 578.7, and its CAS number is 1246751-68-7 (PubChem CID 56599151). P021 was created as a neurotrophic (“nerve-growth-supporting”) research compound, and it is sometimes written P21 or P-21. It is not a medicine you can be prescribed and not a supplement you can legally buy — in the United States P021 exists only as a research chemical.

How does P021 work?

P021’s proposed mechanism, drawn entirely from animal work, centers on brain-derived neurotrophic factor (BDNF) — a signaling protein that acts like fertilizer for neurons, helping them survive, connect, and form new memories. In rodents, P021 appears to raise BDNF activity and encourage neurogenesis, the birth of new neurons in the hippocampus (the brain’s memory hub). Picture a struggling garden: rather than planting fake flowers, P021 is proposed to enrich the soil so the garden can grow its own. Treated rodents also showed less abnormal tau — the protein that tangles up inside neurons in Alzheimer’s disease. The honest caveat: every one of these steps was measured in an animal brain. How, or whether, P021 does any of this in a human brain has not been established (indexed P021 research).

What does the research show?

The P021 evidence is animal evidence — and there is no human study to weigh against it. In mouse models of Alzheimer’s-type disease and of Down syndrome, P021 improved memory and learning, increased markers of new-neuron growth, and reduced abnormal tau compared with untreated animals (indexed P021 research). That is a consistent and encouraging preclinical picture. But the human column is blank: P021 has no registered clinical trial (ClinicalTrials.gov) and no published randomized controlled trial. Some database searches tag P021 papers with a “human” label, but those records are reviews and studies that discuss human Alzheimer’s disease or use human proteins in a dish — not trials that gave P021 to people. So we grade P021 animal-only, none-in-humans: promising in rodents, unknown in humans. That “none-in-humans” flag is the single most important fact on this page — here’s how we grade evidence.

What the community reports

Outside the lab, P021 is far more obscure than headline peptides like BPC-157, and online discussion is thin. The small amount of nootropic-forum chatter that exists describes people trying P021 for memory, focus, or “brain aging,” usually citing the mouse studies. These accounts are anecdotal, and they sit next to a none-in-humans reality: they are not controlled data, they suffer from survivorship bias (people who feel nothing rarely post), and no one is measuring whether anything is actually happening in the brain. Treat them as evidence that people are curious, not as evidence that P021 works.

Is P021 safe? Side effects

P021’s honest safety answer is “we don’t know in humans.” The tolerability information that exists comes from rodent studies, where P021 was given by injection and by mouth without obvious toxic effects — which is a reasonable starting signal, not a safety guarantee for a person. There is no human safety trial and no long-term human data of any kind, so the real-world risks skew toward the practical ones common to every research-chemical peptide: vials sold “for research use only” are unregulated, so their purity, dose accuracy, and sterility are guaranteed by no one. With P021 specifically, there is a second honest unknown — a compound designed to push neuron growth and BDNF signaling has never been watched over years in humans, and no one can yet say what long-term use would do.

FDA & legal status (2026)

P021 is not FDA-approved for anything, and it is not a legal dietary supplement. A Drugs@FDA search returns no approved P021 product, and ClinicalTrials.gov lists no registered human trial as of 2026 — P021 has not entered formal clinical development. In the United States it is sold strictly as a research chemical. This status is current as of July 2026; regulatory positions on research peptides can move, so treat any status claim as dated and re-check it. The full dated breakdown is in the FDA & legal status block above.

How is P021 used, and can it be mixed?

P021 is handled like other research peptides: it is typically supplied as a lyophilized (freeze-dried) powder that has to be reconstituted with bacteriostatic water before use, and the doses that appear in the literature are rodent doses from animal studies — there is no established or studied human dose, and we don’t publish one. If you are working out concentrations, the arithmetic is the same for any peptide — our reconstitution & dosing calculator converts a vial size, a water volume, and a target amount into exact syringe units. People also ask whether research peptides can share a syringe; our mixing compatibility reference covers what is commonly combined and, honestly, where P021 falls into “not enough data” — because for a compound this under-studied, the answer is almost always the latter.

How P021 fits with other nootropic peptides

P021 sits in the nootropic / mental-health peptide family — compounds studied for memory, mood, and brain aging rather than muscle or fat. What sets P021 apart even within that group is how early it is: many nootropic peptides at least have small human studies, while P021’s entire efficacy case is still in mice. That makes it one to watch rather than one to rely on. If a human trial ever begins, it would move P021 up our evidence scale immediately — until then, the animal-only grade stands.

Frequently asked questions

Is P021 proven to work in humans?

No. P021 has repeated animal evidence for better memory, more neurogenesis, and less abnormal tau in mouse models — but zero human trials and no published human data. That makes it a promising preclinical lead, not a proven human nootropic. We grade P021 animal-only, none-in-humans, until a human study reports.

Is P021 legal?

P021 is legal to possess and sell as a research chemical in the United States, but it is not an approved drug and not a legal dietary supplement, and it cannot be sold for human consumption. That is why every vendor lists it “for research use only.”

Is P021 the same as p21 the protein?

No — and this is a common mix-up. The peptide P021 (sometimes written P-21) is a synthetic neurotrophic compound. It is unrelated to “p21,” the cell-cycle protein (p21/CDKN1A) that comes up in cancer and aging biology. Same-looking name, completely different molecule.

Is P021 banned in sport?

Yes. Because P021 has no regulatory approval for human use, it falls under WADA’s S0 “non-approved substances” category and is prohibited at all times for athletes subject to anti-doping rules.

How is P021 taken in the research?

In the animal studies, P021 was given both by injection and orally — the adamantane cap was added specifically to make an oral, brain-penetrant version possible. There is no validated human route or dose; anything you read online about a human protocol is extrapolation, not tested science.

Who is P021 for — and who should be cautious?

P021 draws in people interested in the frontier of memory and brain-aging research — the reader who saw “peptide that regrows neurons in Alzheimer’s mice” and wanted to know what’s real. The honest framing: the rodent case for P021 is one of the more mechanistically interesting in the nootropic-peptide space, touching BDNF, neurogenesis, and tau all at once. But the human efficacy proof isn’t just thin — it doesn’t exist, the long-term safety data doesn’t exist, and the product you’d actually buy is unregulated. Anyone looking for a validated cognitive treatment, and anyone unwilling to be an experiment of one on a compound with zero human data, has every reason to wait for actual human trials.